Sections of mouse tumor tissue were immunohistochemically processed for Ki-67 (a proliferation marker), CD31, and the vascular endothelial growth factor, VEGF (a protein promoting angiogenesis), to explore the antitumor effects on human cervical carcinoma by a synergistic approach consisting of methoxy poly(ethylene glycol)–poly(ε-caprolactone) NPs loaded with paclitaxel (a widely used chemotherapy agent) and radiotherapy. Here, VEGFA is linked to cervical carcinoma.